Growth momentum Australia’s leading regulated bioanalytical CRO with a 30+ year track record and expanding national lab network (Brisbane and Sydney) presents cross-sell opportunities to global biotech and pharma clients seeking GLP/GCP-compliant bioanalysis, high-throughput immunoassays, and gene therapy support.

Advanced tech State-of-the-art platforms (Gyrolab xPlore, MSD Quickplex, BD FACSymphony A3, Cytek Aurora, digital droplet PCR for RNA/siRNA/miRNA, and a large fleet of mass spectrometers) enable handling of complex large and small molecule programs, creating up-sell opportunities for sophisticated bioanalytical methods and biomarker work.

Strategic partnerships Recent collaboration with SGS and leadership changes in business development signal a push to broaden global reach and service scope; leverage these relationships to target multinational biotech firms seeking integrated testing, inspection, and certification capabilities.

Financial potential Revenue range and recent earnings growth (notably EBITDA expansion) indicate a scalable business model; pursue mid-market to large-scale ventures with long-term bioanalysis programs, immunogenicity, PK, and cell/gene therapy studies.

Market positioning Recognition as a top clinical research-focused provider with award-winning reputation and expanding facilities provides a compelling value proposition for firms prioritizing quality, regulatory compliance, and capacity for rapid, high-quality bioanalysis in APAC and globally.